Share Name Share Symbol Market Type Share ISIN Share Description
Abcam Plc LSE:ABC London Ordinary Share GB00B6774699 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 1,306.00 1,307.00 1,309.00 0.00 0.00 - 0.00 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 259.9 56.4 22.0 59.4 2,685

Abcam Share Discussion Threads

Showing 976 to 999 of 1000 messages
Chat Pages: 40  39  38  37  36  35  34  33  32  31  30  29  Older
DateSubjectAuthorDiscuss
15/11/2019
21:21
A beautiful day, nice and blue.
lenzcrafter
15/11/2019
15:40
For those interested in my previous post, big news this week from Open Orphan! Venn Life Sciences, which is part of the ORPH group has been selected as the preferred partner for pharma heavy weights Ipsen Group’s ( Data Management and Biostatistics. The preferred vendor structure will last for a 3-year period. Ipsen had sales in excess of €2.2 billion last year. This partnership has already delivered substantial revenues for the Open Orphan group and positions the business as an integrated drug development partner for Biopharma companies in Europe such as Ipsen. This partnership is the first of many steps to make Venn profitable and deliver a re-rating of the business to be in line with the wider sector. CEO Cathal Friel summaries the significance of the agreement in 2 minute video below. https://www.brrmedia.co.uk/broadcasts-embed/5dc99abe34a3cf1389e844e9/?open-orphan-rns&popup=true
sunningdale1
29/10/2019
11:08
I guess not.
ifthecapfits
04/10/2019
19:46
Sunningdale. Would you be able to explain the implications of ORPH for Abcam? Thanks.
mayers
30/9/2019
12:42
#136 ORPH looks promising to say the least - The new management team has a track record of building successful business and Open Orphan has a clear four pronged growth strategy. The market Open Orphan is targeting is one of the fastest growing in the drug sector with political support behind it and under-supply of treatments for orphan drugs. The end market for Open Orphan is the growing orphan/ rare drug market and the need for consultancy services, particularly in Europe, to launch these products. The orphan drug sector is one of the fastest growing sectors in the global pharmaceutical industry and in the US in 2018 over 50% of all new US Food and Drug Administration approved drugs coming to market are for rare/orphan conditions. In Europe, 57% of all new drugs are orphan designated and globally the orphan/ rare drug market is growing at twice (11%) the pace of the global pharma market
sunningdale1
30/9/2019
12:16
Stumbling!
lenzcrafter
27/9/2019
07:34
jbfnfn,I agree in the importance of the impairment cost. I had assumed that Abcam were earlier indicating that they were about to tidy up their core business with the acquisition of Horizon, but have been pulled back on that because of the need first to come clean on their dreadful ERP programme (I thought it started with SAP!) and to get rid of their FD.
fp optimist
27/9/2019
07:31
#135 I didn't spell it out in #133 but you've analysed the issue better than I could. Oracle products are very bad; they're for governments, inefficient corporations ...
bathcoup
27/9/2019
00:01
"CEO Cathal Friel predicts 40% growth a year" !! That's seriously high. How much confidence does anyone have in that ??
cokehookerscars
26/9/2019
18:59
#133 From the Final results "Enterprise Resource Planning (ERP) programme . . As a result of the changes in the scope and nature of the programme and the usability of historical work performed, software development costs capitalised to date of £12.8m, have been impaired." They capitalised money spent on software and now they have written it off. You can argue that they should never have capitalised it in the first place. A business like this must have scalable top notch IT. They are always going to be spending on IT. It's an expense it shouldn't be capitalised. Have they made a mistake using Oracle for their ERP? It sounds like they have. At least they have realised it and are doing something about it. They should have, or certainly need a strong internal IT ability.
jbfnfn
26/9/2019
12:10
Recently added - great to see ABC bouncing back over the last two days. Open Orphan AIM:ORPH a stock definitely worth keeping tabs on - Rises today and CEO Cathal Friel predicts 40% growth a year on recent podcast below with 2 million of his own money invested. They are currently on a presenting roadshow if anyone is interested hxxps://audioboom.com/posts/7361662-open-orphan-orph-ceo-cathal-friel-tells-alan-green-why-he-expects-40-percent-growth-year-on-year
sunningdale1
11/9/2019
14:37
"GBP12.8 million impairment charge associated with its Oracle Cloud Enterprise Resource Planning programme" How stupid!
bathcoup
10/9/2019
10:25
abc share price imo at bottom support line as i key dyor
buywell3
10/9/2019
10:23
significant fall in the share price might result in it being taken over as the leading antibody company, their cash generative nature and their huge catalogue of 18000 validated antibodies and that would be Britain's only leading life sciences tools company disappearing which would be a shame after Illumina snapped up our sequencing technology.
mw8156
09/9/2019
18:43
And you can bet your bottom dollar it bounces tomorrow by nearly what it's has fell by today.
lenzcrafter
09/9/2019
07:52
It's simple...it always drops on good news! Done
lenzcrafter
09/9/2019
07:48
It is very easy to be wise after the event but buywell sees many before they happen cos he is good at charting see buywell3 9 Jun '19 - 10:43 - 106 of 114 Edit Just to give you guys something to chew one ... the bear case The Chart does stand at a point at which I feel a previous top is being tested IF it fails say due to macro market issues The bottom support suggests 1150p could be tested in a timescale of approx 1 to 2 months based upon the last decent drop. dyor
buywell3
09/9/2019
07:37
City did not like the figures. Sharp rises and sharp falls (in the share price) are normal for this company.
erogenous jones
09/9/2019
06:20
IMO it all comes down to these reported hree numbers in brackets which indicate a loss year ............. 2018/19 2017/18 Operating profit 56.1 68.8 (18.5)% Profit Before Tax (PBT) 56.4 69.1 (18.4)% Diluted earnings per share (EPS) (pence) 21.8p 30.2p (27.8)%
buywell3
09/9/2019
06:04
You watch this bomb today.
lenzcrafter
15/8/2019
14:29
I'm feeling this is a little weak at the moment. Shame as it was on a bit of a climb for the last few months.
lenzcrafter
09/8/2019
07:40
Back in FWIW. Higher Highs, lower lows, and bounced of 12. All looks good to me.
ifthecapfits
23/7/2019
21:37
He’s too busy spouting nonesense on the Fevertree board.
smokybenchod
23/7/2019
12:15
buywell Comments on your position?
phillis
Chat Pages: 40  39  38  37  36  35  34  33  32  31  30  29  Older
Your Recent History
LSE
ABC
Abcam
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191118 07:31:17